OptimizeRx.png
OptimizeRx to Participate in Upcoming Investor Conferences
18. November 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
OptimizeRx Reports Third Quarter 2024 Financial Results
13. November 2024 16:05 ET | OptimizeRx Corporation
- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 ...
OptimizeRx.png
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
31. Oktober 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
10. September 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
09. September 2024 12:00 ET | OptimizeRx Corporation
The availability of Micro-Neighborhood® Targeting on the Company’s Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing ...
OptimizeRx.png
OptimizeRx Reports Second Quarter 2024 Financial Results
08. August 2024 16:05 ET | OptimizeRx Corporation
–   Q2 revenue of $18.8 million, increasing 36% year-over-year–   Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%–   Won 8 DAAP deals during Q2 WALTHAM,...
OptimizeRx.png
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
25. Juli 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
23. Juli 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
15. Juli 2024 07:30 ET | OptimizeRx Corporation
WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...
OptimizeRx.png
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
20. Juni 2024 07:30 ET | OptimizeRx Corporation
• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP...